About Simplexia
Simplexia is develops vaccine against herpes simplex virus type (HSV-2) infection, which is the most common sexually transmitted infection in the world. The infection causes genital herpes with painful and recurrent genital blisters. HSV-2 can also cause life-threatening encephalitis and meningitis in newborns and immunocompromised patients. A major issue is that HSV-2 infected patients also suffer a three-fold increased risk of HIV acquisition.
Leadership at Simplexia
The team at the top of the org chart.
LW
Lena Degling Wikingsson
Chairman Of The Board Of Directors
Open Jobs at Simplexia (18)
Sort
- Simplexia · Stockholm, SE · 2d
- Simplexia · Stockholm, SE · 3d
- Simplexia · Oslo, NO / Norge, NO · 10d
- Simplexia · Mellersta Sverige, SE · 14d
- Simplexia · Stockholm, SE · 16d
- Simplexia · Västerås, SE · 18d
- Simplexia · Göteborg, Europe, SE · 21d
- Simplexia · Umeå, SE · 23d
- Simplexia · Sverige, SE · 1mo
- Simplexia · Stockholm, Europe, SE · 2mo
- Simplexia · Stockholm, SE · 2mo
- Simplexia · Uppsala, SE · 2mo
- Simplexia · Stockholm, SE · 3mo
- Simplexia · Uppsala, SE · 3mo
- Simplexia · Sverige, SE / Stockholm, SE · 4mo
- Simplexia · Malmö, SE / Stockholm, SE · 4mo
- Simplexia · Västerås, SE · 5mo
- Simplexia · Stockholm, SE · 5mo
Similar companies hiring
Top employers in Health Care